Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
41
AMGXF Quote, Financials, Valuation and Earnings
Last price:
$0.36
Seasonality move
:
-8.67%
Day range:
$0.36 - $0.36
52-week range:
$0.36 - $0.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.32x
P/B ratio:
7.09x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$139.1M
Revenue:
$5.8M
EPS (TTM):
-$0.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMGXF
AnGes, Inc.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SNBIF
SanBio Co., Ltd.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMGXF
AnGes, Inc.
|
$0.36 | -- | $139.1M | -- | $0.00 | 0% | 20.32x |
|
HLOSF
Healios KK
|
$2.10 | -- | $243M | -- | $0.00 | 0% | 329.74x |
|
PPTDF
PeptiDream Inc.
|
$10.42 | -- | $1.3B | 13.79x | $0.00 | 0% | 11.22x |
|
SNBIF
SanBio Co., Ltd.
|
$10.11 | -- | $788.9M | -- | $0.00 | 0% | 279.12x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.44 | -- | $492.3M | -- | $0.00 | 0% | 2.47x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMGXF
AnGes, Inc.
|
1.74% | 0.000 | 0.25% | 0.89x |
|
HLOSF
Healios KK
|
47.23% | -0.193 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.074 | 8.66% | 4.05x |
|
SNBIF
SanBio Co., Ltd.
|
72.5% | -0.974 | 0.51% | 4.37x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
48.47% | 1.070 | 73.82% | 1.61x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMGXF
AnGes, Inc.
|
$399.5K | -$10.4M | -153.93% | -162.7% | -703% | -- |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SNBIF
SanBio Co., Ltd.
|
-$13K | -$5.3M | -156.97% | -284.71% | -- | -$10.9M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$37.1M | -$8.9M | -9.66% | -19.06% | -17.59% | -$1M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
AnGes, Inc. vs. Competitors
-
Which has Higher Returns AMGXF or HLOSF?
Healios KK has a net margin of -190.55% compared to AnGes, Inc.'s net margin of -9751.87%. AnGes, Inc.'s return on equity of -162.7% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital AMGXFAnGes, Inc.27% -$0.01 $20M HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About AMGXF or HLOSF?
AnGes, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes, Inc. has higher upside potential than Healios KK, analysts believe AnGes, Inc. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings AMGXFAnGes, Inc.0 0 0 HLOSFHealios KK0 0 0 -
Is AMGXF or HLOSF More Risky?
AnGes, Inc. has a beta of 0.068, which suggesting that the stock is 93.218% less volatile than S&P 500. In comparison Healios KK has a beta of 0.262, suggesting its less volatile than the S&P 500 by 73.819%.
-
Which is a Better Dividend Stock AMGXF or HLOSF?
AnGes, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes, Inc. pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMGXF or HLOSF?
AnGes, Inc. quarterly revenues are $1.5M, which are larger than Healios KK quarterly revenues of $128.8K. AnGes, Inc.'s net income of -$2.8M is lower than Healios KK's net income of $3.8M. Notably, AnGes, Inc.'s price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes, Inc. is 20.32x versus 329.74x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMGXFAnGes, Inc.20.32x -- $1.5M -$2.8M HLOSFHealios KK329.74x -- $128.8K $3.8M
-
Which has Higher Returns AMGXF or PPTDF?
PeptiDream Inc. has a net margin of -190.55% compared to AnGes, Inc.'s net margin of -25.38%. AnGes, Inc.'s return on equity of -162.7% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital AMGXFAnGes, Inc.27% -$0.01 $20M PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About AMGXF or PPTDF?
AnGes, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes, Inc. has higher upside potential than PeptiDream Inc., analysts believe AnGes, Inc. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMGXFAnGes, Inc.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is AMGXF or PPTDF More Risky?
AnGes, Inc. has a beta of 0.068, which suggesting that the stock is 93.218% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.573, suggesting its less volatile than the S&P 500 by 42.666%.
-
Which is a Better Dividend Stock AMGXF or PPTDF?
AnGes, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes, Inc. pays -- of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMGXF or PPTDF?
AnGes, Inc. quarterly revenues are $1.5M, which are smaller than PeptiDream Inc. quarterly revenues of $29.3M. AnGes, Inc.'s net income of -$2.8M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, AnGes, Inc.'s price-to-earnings ratio is -- while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes, Inc. is 20.32x versus 11.22x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMGXFAnGes, Inc.20.32x -- $1.5M -$2.8M PPTDFPeptiDream Inc.11.22x 13.79x $29.3M -$7.4M
-
Which has Higher Returns AMGXF or SNBIF?
SanBio Co., Ltd. has a net margin of -190.55% compared to AnGes, Inc.'s net margin of --. AnGes, Inc.'s return on equity of -162.7% beat SanBio Co., Ltd.'s return on equity of -284.71%.
Company Gross Margin Earnings Per Share Invested Capital AMGXFAnGes, Inc.27% -$0.01 $20M SNBIFSanBio Co., Ltd.-- -$0.07 $11.6M -
What do Analysts Say About AMGXF or SNBIF?
AnGes, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand SanBio Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes, Inc. has higher upside potential than SanBio Co., Ltd., analysts believe AnGes, Inc. is more attractive than SanBio Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings AMGXFAnGes, Inc.0 0 0 SNBIFSanBio Co., Ltd.0 0 0 -
Is AMGXF or SNBIF More Risky?
AnGes, Inc. has a beta of 0.068, which suggesting that the stock is 93.218% less volatile than S&P 500. In comparison SanBio Co., Ltd. has a beta of -0.527, suggesting its less volatile than the S&P 500 by 152.659%.
-
Which is a Better Dividend Stock AMGXF or SNBIF?
AnGes, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SanBio Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes, Inc. pays -- of its earnings as a dividend. SanBio Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMGXF or SNBIF?
AnGes, Inc. quarterly revenues are $1.5M, which are larger than SanBio Co., Ltd. quarterly revenues of --. AnGes, Inc.'s net income of -$2.8M is higher than SanBio Co., Ltd.'s net income of -$4.8M. Notably, AnGes, Inc.'s price-to-earnings ratio is -- while SanBio Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes, Inc. is 20.32x versus 279.12x for SanBio Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMGXFAnGes, Inc.20.32x -- $1.5M -$2.8M SNBIFSanBio Co., Ltd.279.12x -- -- -$4.8M
-
Which has Higher Returns AMGXF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of -190.55% compared to AnGes, Inc.'s net margin of -99.41%. AnGes, Inc.'s return on equity of -162.7% beat Nxera Pharma Co., Ltd.'s return on equity of -19.06%.
Company Gross Margin Earnings Per Share Invested Capital AMGXFAnGes, Inc.27% -$0.01 $20M SOLTFNxera Pharma Co., Ltd.73.58% -$0.55 $755.2M -
What do Analysts Say About AMGXF or SOLTF?
AnGes, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes, Inc. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe AnGes, Inc. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings AMGXFAnGes, Inc.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is AMGXF or SOLTF More Risky?
AnGes, Inc. has a beta of 0.068, which suggesting that the stock is 93.218% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.018, suggesting its less volatile than the S&P 500 by 98.16%.
-
Which is a Better Dividend Stock AMGXF or SOLTF?
AnGes, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes, Inc. pays -- of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMGXF or SOLTF?
AnGes, Inc. quarterly revenues are $1.5M, which are smaller than Nxera Pharma Co., Ltd. quarterly revenues of $50.4M. AnGes, Inc.'s net income of -$2.8M is higher than Nxera Pharma Co., Ltd.'s net income of -$50.1M. Notably, AnGes, Inc.'s price-to-earnings ratio is -- while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes, Inc. is 20.32x versus 2.47x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMGXFAnGes, Inc.20.32x -- $1.5M -$2.8M SOLTFNxera Pharma Co., Ltd.2.47x -- $50.4M -$50.1M
-
Which has Higher Returns AMGXF or STMM?
Stemcell Holdings, Inc. has a net margin of -190.55% compared to AnGes, Inc.'s net margin of --. AnGes, Inc.'s return on equity of -162.7% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AMGXFAnGes, Inc.27% -$0.01 $20M STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About AMGXF or STMM?
AnGes, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that AnGes, Inc. has higher upside potential than Stemcell Holdings, Inc., analysts believe AnGes, Inc. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMGXFAnGes, Inc.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is AMGXF or STMM More Risky?
AnGes, Inc. has a beta of 0.068, which suggesting that the stock is 93.218% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AMGXF or STMM?
AnGes, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnGes, Inc. pays -- of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMGXF or STMM?
AnGes, Inc. quarterly revenues are $1.5M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. AnGes, Inc.'s net income of -$2.8M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, AnGes, Inc.'s price-to-earnings ratio is -- while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnGes, Inc. is 20.32x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMGXFAnGes, Inc.20.32x -- $1.5M -$2.8M STMMStemcell Holdings, Inc.0.17x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
